AbbVie Inc. (NYSE:ABBV) Announces Quarterly Dividend of $1.73

AbbVie Inc. (NYSE:ABBV) declared a quarterly dividend on Thursday, February 19th. Investors of record on Wednesday, April 15th will be paid a dividend of 1.73 per share on Friday, May 15th. This represents a c) dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Wednesday, April 15th.

AbbVie has increased its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 53 years. AbbVie has a payout ratio of 49.5% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect AbbVie to earn $13.98 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 49.5%.

AbbVie Trading Down 2.0%

AbbVie stock opened at $224.13 on Friday. AbbVie has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a market capitalization of $396.12 billion, a price-to-earnings ratio of 94.97, a P/E/G ratio of 0.80 and a beta of 0.35. The firm has a 50 day moving average of $224.01 and a 200 day moving average of $221.70.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company’s revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts predict that AbbVie will post 12.31 EPS for the current year.

Institutional Investors Weigh In On AbbVie

Institutional investors have recently modified their holdings of the stock. Vancity Investment Management Ltd bought a new position in shares of AbbVie during the 4th quarter valued at approximately $210,000. Mcguire Capital Advisors Inc. bought a new position in AbbVie during the fourth quarter valued at $1,136,000. Hamilton Wealth LLC raised its stake in shares of AbbVie by 4.7% in the fourth quarter. Hamilton Wealth LLC now owns 22,224 shares of the company’s stock valued at $5,078,000 after acquiring an additional 995 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of AbbVie by 38.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 25,847 shares of the company’s stock worth $5,906,000 after acquiring an additional 7,116 shares during the last quarter. Finally, WealthPoint Financial LLC purchased a new position in shares of AbbVie during the 4th quarter worth about $436,000. 70.23% of the stock is owned by institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.